Bellerophon Therapeutics has a fifty-two week low of $0.37 and a fifty-two week high of $12.58.

Source: https://www.etfdailynews.com/2023/09/06/bellerophon-therapeutics-nasdaqblph-research-coverage-started-at-stocknews-com/

Bellerophon Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

Source: https://www.americanbankingnews.com/2023/01/27/bellerophon-therapeutics-inc-nasdaqblph-short-interest-up-1450-0-in-january.html

Finally, upgraded Bellerophon Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 17th.

Source: https://www.americanbankingnews.com/2023/05/31/bellerophon-therapeutics-nasdaqblph-stock-price-crosses-below-50-day-moving-average-of-8-87.html

Will Bellerophon gave up some of those gains, the stock is still up nearly 130% over the last three months.

Source: https://investorplace.com/market360/2023/01/7-micro-cap-stocks-to-buy-for-risk-taking-investors/